This HTML5 document contains 179 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q45957143
rdf:type
wikibase:Item
schema:description
научни чланак научна статия artículo científico publicado en 2015 2015年學術文章 bilimsel makale wissenschaftlicher Artikel artigo científico vitenskapelig artikkel مقالة علمية نشرت في 16 يناير 2015 bài báo khoa học научни чланак 2015 nî lūn-bûn 2015年の論文 2015年學術文章 scientific article published on 16 January 2015 artigo científico vitskapeleg artikkel scientific article published on 16 January 2015 tieteellinen artikkeli 2015年學術文章 наукова стаття, опублікована в січні 2015 artikull shkencor מאמר מדעי vetenskaplig artikel научная статья სამეცნიერო სტატია мақолаи илмӣ ১৬ জানুয়ারি ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2015年学术文章 articolo scientifico vedecký článok 2015年學術文章 naučni članak wetenschappelijk artikel บทความทางวิทยาศาสตร์ artikel ilmiah article scientifique 2015年学术文章 2015年学术文章 article científic scienca artikolo 2015年学术文章 videnskabelig artikel 2015年学术文章 2015年學術文章 artykuł naukowy artikulong pang-agham scientific article published on 16 January 2015 artigo científico articol științific vědecký článek artículu científicu 2015年学术文章 teaduslik artikkel tudományos cikk επιστημονικό άρθρο article scientific 2015년 논문
p:P577
wds:Q45957143-7E0F6544-DEA6-42D0-B878-C94B4AD41998
wdt:P577
2015-01-16T00:00:00Z
p:P2860
wds:Q45957143-4F7D0791-7E4A-4CE7-B01A-538088041400 wds:Q45957143-55AF003E-8990-447D-8ED6-AF7D6E05B760 wds:Q45957143-55DA2FA8-DBB5-4176-B1B4-815256FCA94B wds:Q45957143-2D7048EA-4F8A-420C-912C-91FCB5A89F26 wds:Q45957143-3BEE30FC-B473-4736-97C4-9359F06B1127 wds:Q45957143-42C73397-370F-45AD-BAE8-4360D49A0F8C wds:Q45957143-46AE9ACC-B856-4C2C-9D18-328053573E6E wds:Q45957143-0C80434C-931B-4B1D-972B-C0A4BE61E916 wds:Q45957143-ECE76F98-636C-4EA6-82FD-81E5E03FDA35 wds:Q45957143-F231EDAA-CB4C-472E-A4E2-84E59A146D07 wds:Q45957143-AE410CFE-B62C-4C0C-97C2-2F7C08A03EF4 wds:Q45957143-E0091108-8189-4285-A3D8-FA15557267DC wds:Q45957143-E1E9049F-C4D5-4197-A254-8D4096FD9595 wds:Q45957143-A7A98DFA-F28A-4AD4-A9A7-5ACA0A913DB2 wds:Q45957143-ACAE76BC-8DF3-417B-9FA7-6E892C68B0D0 wds:Q45957143-5DABD9D3-B65C-4547-9504-2F99AF105D73 wds:Q45957143-6B738957-3E4B-40F5-B23E-BEBD1EF92892 wds:Q45957143-71B3FB1B-9B65-49EE-8D60-7AA1F74342F1
wdt:P2860
wd:Q38994189 wd:Q40239582 wd:Q24612084 wd:Q29616123 wd:Q29616218 wd:Q48161067 wd:Q29620155 wd:Q28275476 wd:Q34422206 wd:Q29617512 wd:Q54710973 wd:Q27860648 wd:Q29617511 wd:Q27853062 wd:Q84163431 wd:Q47931535 wd:Q74696960 wd:Q29617472
p:P2093
wds:Q45957143-A87BDFEF-3032-4321-A253-0F38FD06AA62 wds:Q45957143-9A7BCFD6-3F9C-49B4-9D21-E3C769171252 wds:Q45957143-91DDA3C8-87C7-47AC-8483-2B85731B9C53 wds:Q45957143-94F5AD61-FF81-48A3-88E6-0F235595A807 wds:Q45957143-8B3FDC1D-3551-4014-9FDD-6B89ADAD46A8 wds:Q45957143-8BA19BD6-3D80-40CA-A366-79F342FC35F3 wds:Q45957143-8694FB99-563F-4B7B-8DB0-B2E1EC2F92AB wds:Q45957143-894857FA-8057-43BD-AF84-B3C617DF1D4D wds:Q45957143-6552C659-EF17-4F53-97F1-74267D6B4F56 wds:Q45957143-6265E115-AB5B-40D7-B946-4AB9CC86A21E wds:Q45957143-E6F2C3C7-20C7-4673-B5DA-F585687658AF wds:Q45957143-E7AAC798-A2DE-4870-B580-435109468AA0 wds:Q45957143-AD55CAE4-F980-4C18-B46A-28DE2AA3D8F5 wds:Q45957143-01077E59-919B-4013-AAA5-CB5BC0087515 wds:Q45957143-07545023-B121-4BA3-818E-CC766071A551 wds:Q45957143-52FAB849-7683-4083-AF9F-8B031CD006FD wds:Q45957143-51E45DB4-7FF6-4259-AF6C-3701A53A633C wds:Q45957143-47FB29A7-54A6-46F5-9BC2-AE6CE9C42148 wds:Q45957143-4B6B6A8C-4064-4FD2-9FC6-BDD18387868E wds:Q45957143-3ACB07F3-D6BF-457B-9C2C-AD93B5B82BB5 wds:Q45957143-283409A6-A6E7-4028-94A3-D5A2D1660D62
wdt:P2093
Peter De Porre Johann S de Bono Christopher J Logothetis Paul de Souza Vahid Naini Youn C Park Matthew R Smith Kurt Miller Jinhui Li Thian Kheoh Eric J Small Cora N Sternberg Thomas W Griffin Peter F A Mulders Margaret K Yu COU-AA-302 Investigators Arturo Molina Thomas W Flaig Charles J Ryan Neal D Shore Celestia S Higano
rdfs:label
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3
skos:prefLabel
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3
schema:name
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3
p:P50
wds:Q45957143-F547A9C1-1207-4BA3-A92C-1AAECC625263 wds:Q45957143-E7C22014-DC60-49EB-9A58-5CBA754C8BED wds:Q45957143-1264F8D6-FE94-4FBE-B9DA-912787CEA316 wds:Q45957143-23288FD5-DE63-4C8E-BC84-64288BE21AE1 wds:Q45957143-4235654F-5ED1-4569-A104-22179D89B7EE
wdt:P50
wd:Q73569107 wd:Q88065306 wd:Q58928904 wd:Q38546550 wd:Q80164282
p:P1476
wds:Q45957143-CFB3037D-DBF1-4AE2-BD6C-93B1C55C239F
wdt:P1476
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3
p:P304
wds:Q45957143-F2287F8D-5475-4A62-B923-F37305798F94
wdt:P304
152-160
p:P31
wds:Q45957143-E32D99E9-0809-4026-97E2-4207C9E3FF45
wdt:P31
wd:Q13442814
p:P921
wds:Q45957143-EA505E01-656E-4D80-A79B-1819A9B3B4B1 wds:Q45957143-FB91FE08-3CCE-4EF6-A5A3-EF1EBE68D4D2 wds:Q45957143-1B08E1D1-FDED-4BFF-BBB4-BD6CDB12F739
wdt:P921
wd:Q181257 wd:Q974135 wd:Q269829
p:P698
wds:Q45957143-B527D330-D9EE-49C7-8FA0-D36211C4DC04
wdtn:P698
n9:25601341
wdt:P698
25601341
p:P1433
wds:Q45957143-586CEA4D-FD5D-4C99-8B32-B977CAC62F2C
wdt:P1433
wd:Q13747613
p:P433
wds:Q45957143-C0CED64A-0DB9-4DF8-9523-97779BC0734D
p:P478
wds:Q45957143-38CC7581-5A7E-4C01-8911-8DA9760A4746
wdt:P433
2
wdt:P478
16
p:P356
wds:Q45957143-FD12DF7A-1EC5-48F4-8EB3-0711B6F2774B
wdtn:P356
n11:S1470-2045(14)71205-7
wdt:P356
10.1016/S1470-2045(14)71205-7